Stocks Health care FBRX
NASDAQ · Health careForte Biosciences, Inc. (FBRX)
It posted a net loss of $87.9M. In fiscal 2025 capital spending exceeded operating cash flow by $51M. At June 30, 2026 it held $49.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Forte Biosciences, Inc. does
Forte Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FBRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$69.4M | -$4.71 | -$51M |
| 2024 | n/a | -$35.5M | -$12.17 | -$30.8M |
| 2023 | n/a | -$31.5M | -$24.92 | -$28.8M |
| 2022 | n/a | -$13.9M | -$19.94 | n/a |
| 2021 | n/a | -$21.7M | -$38.63 | n/a |
| 2020 | n/a | -$46.5M | -$157.49 | n/a |
Latest SEC filings
What Forte Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026Deregistration 15-12G
- September 8, 2026Deregistration 15-12G
- September 8, 2026Deregistration 15-12G
- August 27, 2026Form POS AM filing POS AM
- August 27, 2026Form POS AM filing POS AM
- August 27, 2026Form POS AM filing POS AM
- August 27, 2026Form POS AM filing POS AM
- August 27, 2026Form POS AM filing POS AM
- August 27, 2026Form POS AM filing POS AM
- August 27, 2026Form S-8 POS filing S-8 POS
Questions about FBRX
What does Forte Biosciences, Inc. do?
Forte Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FBRX.
Is Forte Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $87.9M.
When did Forte Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the deregistration from September 8, 2026.
Similar companies
Follow FBRX
Get an email when Forte Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow FBRX: get an email when it filesWhere the numbers come from
Financial figures are the values Forte Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.